Inventiva (IVEVF) Liabilities and Shareholders Equity (2018 - 2025)
Inventiva (IVEVF) posted Liabilities and Shareholders Equity of $290.4 million for Q4 2025, up 43.38% on a QoQ basis from $202.6 million in Q2 2025, and up 128.46% year-over-year from $127.1 million in Q4 2024.
Analysis
Inventiva (IVEVF) Liabilities and Shareholders Equity (2018 - 2025) Analysis & Trends
Inventiva has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $290.4 million in Q4 2025.
- On a quarterly basis, Liabilities and Shareholders Equity rose 128.46% year-over-year to $290.4 million in Q4 2025; TTM through Dec 2025 was $640.9 million, a 113.76% increase from a year earlier, with the FY2025 full-year figure at $290.4 million, up 128.46% from the prior year.
- Liabilities and Shareholders Equity was $290.4 million for Q4 2025 at Inventiva, up from $202.6 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $290.4 million in Q4 2025, with the low at $20.7 million in Q2 2024.
- Average Liabilities and Shareholders Equity over 5 years is $133.4 million, with a median of $127.1 million recorded in 2024.
- The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity plunged 73.14% in 2024, then jumped 878.04% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $139.5 million in 2021, then dropped by 15.19% to $118.4 million in 2022, then tumbled by 36.76% to $74.8 million in 2023, then jumped by 69.86% to $127.1 million in 2024, then surged by 128.46% to $290.4 million in 2025.
- The last three Liabilities and Shareholders Equity figures came in at $290.4 million (Q4 2025), $202.6 million (Q2 2025), and $127.1 million (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 442.18 Bn | 435.61 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 366.59 Bn | 359.45 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 266.49 Bn | 258.80 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Pfizer | 159.09 Bn | 147.39 Bn | 10.94 Bn | 201.13 Bn |
| 6 | Sanofi | 52.34 Bn | 44.96 Bn | 10.79 Bn | 150.01 Bn |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 4.32 Bn |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 7.87 Bn |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn | 7.22 Bn |
| 10 | Inventiva | 693.72 Mn | 693.72 Mn | - | 290.44 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 290.44 Mn |
| Jun 30, 2025 | 202.57 Mn |
| Dec 31, 2024 | 127.13 Mn |
| Jun 30, 2024 | 20.71 Mn |
| Dec 31, 2023 | 74.84 Mn |
| Jun 30, 2023 | 77.12 Mn |
| Dec 31, 2022 | 118.35 Mn |
| Jun 30, 2022 | 115.66 Mn |
| Dec 31, 2021 | 139.55 Mn |
| Jun 30, 2021 | 141.16 Mn |
| Mar 31, 2021 | 159.49 Mn |
| Dec 31, 2020 | 165.63 Mn |
| Jun 30, 2020 | 75.70 Mn |
| Dec 31, 2019 | 63.05 Mn |
| Dec 31, 2018 | 91.10 Mn |